Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC
Pasi Antero Janne, BC Wang, Byoung Chul Cho, Jun Zhao, Jiaqi Li, Maximilian Johannes Hochmair and 11 more
- Rank
- 88 of 3,639
- Percentile
- top 2.5%
- Where
- Annals of Oncology, 2023
- Citations
- 36
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.